ArticleScientific reports2026
Implementation of SARS-CoV-2 genomic surveillance during the COVID-19 pandemic through an academic-public health collaboration in southeast Michigan.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Regional genomic surveillance is essential for tracking viral evolution and informing targeted public health responses. During the COVID-19 pandemic, we established a collaborative genomic surveillance pipeline for SARS-CoV-2 in Southeast Michigan to support national surveillance efforts and guide local pandemic response strategies. This work aims to present the methods and resources we have achieved during this effort and demonstrates the feasibility of such a collaboration. A partnership between Wayne State University (WSU), the Detroit Health Department (DHD), Henry Ford Health (HFH), the Wayne Health Mobile Unit (WHMU), and the Michigan Department of Health and Human Services (MDHHS) was established to collect, sequence, and analyze SARS-CoV-2 samples. Samples underwent automated nucleic acid extraction, RT-qPCR testing, and whole genomic sequencing at WSU's integrative biosciences center (IBio). We analyzed consensus genome sequences using high-performance computing infrastructure for lineage assignment and variant identification. Between January 2022 and July 2024, we collected and archived 7508 samples, with 6235 (83.0%) successfully sequenced. A sub-analysis of 4637 HFH samples explored geographic distributions across 295 Michigan ZIP codes. Compared to the overall proportion of deaths among all people with SARS-CoV-2 positive tests in the sample (3.6% [95% CI (3.1, 4.2)]), the case-fatality rate was significantly increased with the 19 A + B [7.69%, 95% CI (5.03, 11.58)] and 20A (European 2 lineage: EU2) [9.65%, 95% CI (7.72, 11.99)] variants. The frequency distributions of variants showed a strong correlation (r = 0.98) with Michigan's statewide data reported in GISAID. Omicron was the most prevalent variant detected (64% of cases). Our program demonstrated capacity for academic-public health partnerships to detect SARS-CoV-2 variant circulation in Southeast Michigan. This framework provides a replicable model for future pathogen surveillance programs to build on in response to infectious disease outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.